- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
340B: Additional Burdens
In addition to the challenges surrounding the 340B Drug Pricing Program previously discussed by the managed care stakeholders during this Oncology Stakeholders Summit, Spring 2015 series, Ted Okon, MBA, describes some other ways the consolidation between clinics and hospitals impacts patients.
Mr Okon notes that when consolidation takes place, cancer patients who are in the middle of their course of treatment are sometimes burdened by a sudden increase in the price of their treatments. In some instances, the cost of treatment may rise by 50%.
In addition to being impacted by rising fees, adds Mr Okon, patients are being asked to split up combination therapy, especially in diseases such as multiple myeloma, where patients are treated with a combination of brand drugs and generics. Patients are administered certain medications in a clinic setting, but are then directed to travel to a hospital to receive the rest of their medications so that hospitals may take advantage of the financial benefits of the 340B program, explains Mr Okon.
If the issues surrounding the 340B Drug Pricing Program are not addressed soon, the introduction of oversight will hurt patients, notes Scott Gottlieb, MD.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
